Enjoy Free Shipping on your First Order

PEPTIDES SOURCE

Search
Close this search box.
Product List

MK 677

Key Takeaways of Ibutamoren (MK 677)

  • Ibutamoren, commonly known as MK-677, is a growth hormone secretagogue that stimulates the pituitary gland to release more growth hormone and insulin-like growth factor 1 (IGF-1).
  • MK-677 benefits include improved muscle mass, fat loss, healthy bones, improved cognitive function, enhanced wound healing and tissue regeneration, healthy heart, strong immune system, improved sex drive and sexual function, improved blood sugar levels, and improved cholesterol profile.
  • MK-677 has several potential advantages over anabolic steroids, as it promotes muscle growth, increases bone mineral density, and aids in recovery without the adverse side effects associated with traditional steroids. Unlike traditional anabolic steroids, MK-677 is considered safer and does not suppress natural hormone production, making it a promising option for muscle growth without major side effects.
  • The usual recommended dosage range for MK-677 is between 10-25 mg per day, typically administered once daily. However, some individuals may prefer dividing the dosage into two or three smaller administrations. To ensure safety and effectiveness, it is advisable to commence with a lower dose and incrementally adjust until finding the optimal dosage that suits your needs.
  • When considering purchasing MK-677, it is crucial to ensure that you obtain it from a legally accredited US pharmacy. It is recommended to do so only under the guidance and prescription of a qualified weight loss doctor who can tailor the dosage and treatment plan specifically for your individual needs and health condition. Buying MK-677 from reputable sources and following your doctor’s instructions will help ensure its quality, safety, and effectiveness in supporting your weight loss journey.

Potential Benefits of Ibutamoren (MK 677)

MK 677 offers a variety of benefits, including improving lean muscle mass, promoting fat loss, maintaining a healthy skeletal frame, enhancing sleep quality, and boosting cognitive function. Additionally, it accelerates wound healing, supports heart health, strengthens the immune system, enhances sexual function and drive, improves blood sugar levels, and positively influences cholesterol profiles.

  • Improves lean muscle mass and promotes fat loss [3-26]
  • Maintains a healthy skeletal frame [27-56]
  • Improves sleep quality [57-81]
  • Improves cognitive function [82-136]
  • Accelerates wound healing and tissue regeneration [137-150]
  • Maintains a healthy heart [151-202]
  • Strengthens the immune system [203-240]
  • Improves sex drive and sexual function [241-273]
  • Improves blood sugar levels [273-308]
  • Improves cholesterol profile [309-332]

What is Ibutamoren (MK 677)?

MK-677, also known as MK 677, ibutamoren, or ibutamoren mesylate, belongs to a group called growth hormone secretagogues. They are substances that boost growth hormone production. MK-677 can also increase the production of insulin-like growth factor 1 (IGF-1), a hormone similar in molecular structure and function to insulin. The ability of MK-677 to boost the levels of GH and IGF-1 is associated with a wide array of health benefits.

Discover the transformative power of Growth Hormone Boosting Peptides for enhanced muscle growth and recovery. Explore our cutting-edge peptides collection to unlock your body’s full potential. Elevate your fitness journey with science-backed solutions to optimize your growth hormone levels today!

How Ibutamoren (MK 677) Works

The exact mechanism by which Ibutamoren (MK 677) exerts these effects is by mimicking the action of the hunger hormone ghrelin and binding to one of the growth hormone secretagogue receptors (GHSR) in the brain. [1] This in turn boosts growth hormone (GH) levels. Interestingly, GHSR is located in certain regions of the brain that regulate appetite, mood, pleasure, and cognitive function. [2] Because of this, researchers believe that MK-677 can have beneficial effects on these functions.

In addition, MK-677 is also classified as a selective androgen receptor modulator (SARM), a class of therapeutic compounds similar in function to anabolic agents, but with lesser side effects. This makes MK-677 a safe and effective form of GH and IGF-1 replacement therapy.

Research on Ibutamoren (MK 677)

A Improves Lean Muscle Mass and Promotes Fat Loss

Ibutamoren (MK 677) can produce a peak GH response by stimulating the release of growth hormone from the pituitary gland, leading to a sudden increase in circulating GH levels in the bloodstream. This peak response is observed shortly after ingestion and contributes to the various benefits associated with MK-677, such as enhanced muscle growth, fat loss, and improved body composition.

MK-677 is frequently used as an anabolic substance, which means that it can produce physical benefits such as increased muscle mass and strength as well as fat loss. Studies show that this powerful compound can help improve body composition and prevent muscle wasting related to old age and other medical conditions:

  1. In obese males, oral treatment with MK-677 increased fat-free mass by boosting basal metabolic rate (BMR), the rate at which the body uses energy while at rest. [3]
  2. Several high-quality studies showed that higher GH levels were strongly linked with increased muscle mass and strength in the elderly, suggesting that MK-677 supplementation may have positive effects. [4-13]
  3. Several lines of evidence also suggested that higher IGF-1 levels were associated with increased muscle mass and strength in the older population. [14-22]
  4. In patients with muscle wasting, MK-677 reversed diet-induced nitrogen wasting with higher tolerability and without clinically significant adverse experiences. Neither the serum cortisol response nor the PRL response showed a significant increase after 7 days of MK-677 dosing when compared with 7 days of placebo. There was no significant difference in IGF binding protein-2 observed between the MK-677 and placebo treatments. [23]
  5. In patients recovering from hip fracture, MK-677 treatment improved gait speed and stair climbing power, which is suggestive of improved muscle function. [24]
  6. In healthy older adults, 12 months of MK-677 treatment significantly increased fat-free mass without any adverse side effects. [25]
  7. In GH-deficient adults, MK-677 administration improved body composition by increasing IGF-1 levels. [26]

Discover the power of Peptides for Weight Loss – Explore more options now! Take the first step towards your weight loss goals today.

B. Maintains a Healthy Skeletal Frame

MK-677 belongs to a class of drugs known as growth hormone secretagogues, which work by stimulating the pituitary gland to produce and release more growth hormones. This enhanced production of growth hormone, along with the increased release of insulin-like growth factor 1 (IGF-1), plays a crucial role in promoting various physiological processes. One notable benefit of MK-677 is its ability to increase bone mineral density, which can be particularly beneficial for individuals looking to enhance bone health and strength.

Increased growth hormone and IGF-1 improve bone health by stimulating the cells responsible for bone formation, leading to higher bone density and strength. These hormones promote the synthesis of new bone tissue and help maintain bone mass, reducing the risk of fractures and promoting overall bone health. Clinical studies support MK-677’s ability to increase bone density and improve overall bone health:

  1. In healthy obese males, MK-677 treatment for 2 weeks improved bone turnover (total volume of bone formed and broken down). [27]
  2. In elderly adults (65 years or older), oral MK-677 treatment daily for 2 weeks improved bone building by increasing osteocalcin, a marker of bone turnover. [28]
  3. In postmenopausal women with osteoporosis, MK-677 treatment for 12 months improved bone mineral density in the femoral neck. [29]
  4. In patients with hip fracture (no more than 18 days post-fracture), daily treatment with MK-677 for 6 months resulted in greater improvement in three of four lower extremity functional performance measures and in the ability to live independently compared with placebo treatment. [30]
  5. A study reported that increased GH can stimulate the mobilization of endothelial progenitor cells (EPCs) from the bone marrow to the sites of injury, suggesting that MK-677 can help repair damaged bones. [31]
  6. A study found that MK-677 can improve bone health by increasing the activity of osteoblasts (bone cells). [32]
  7. By increasing GH levels, MK-677 can significantly lower the risk of osteoporosis, fractures, and other bone disorders. [33-45]
  8. By boosting IGF-1 levels, MK-677 can also help lower the prevalence of various bone disorders. [46-56]

C. Improves Sleep Quality

Enhanced release of growth hormone induced by MK-677 promotes good sleep because growth hormone plays a crucial role in regulating the sleep-wake cycle. It helps improve the quality of sleep by increasing the time spent in deep, restorative sleep stages. Additionally, growth hormone aids in muscle repair and recovery during sleep, leading to a more restful and rejuvenating sleep experience. As a result, individuals taking MK-677 often experience better sleep patterns and overall sleep quality.

The aging population is highly at risk for sleep problems and disorders that can significantly affect the quality of life. Whether it is age-related or caused by a certain medical condition, Ibutamoren (MK 677) supplementation may help improve sleep quality and quantity according to numerous clinical trials:

  1. In both younger and elderly subjects, MK-677 treatment for 14 days improved sleep quality by increasing rapid eye movement (REM) sleep duration by 50%. [57]
  2. In healthy older adults, oral administration of MK-677 (25 mg) once daily improved the Pittsburgh Sleep Quality Index, a measure of sleep. [58]
  3. In normal men, the administration of growth hormone secretagogue increases slow-wave sleep (SWS), which is often referred to as deep sleep. [59]
  4. In young healthy men, intravenous injections of growth hormone secretagogue during sleep consistently stimulated slow-wave sleep, suggesting that MK-677 may help improve sleep quality. [60]
  5. In healthy young adults, growth hormone secretagogue administration increases stage 2 sleep. [61]
  6. Higher GH levels are strongly associated with improved deep sleep stage, indicating that MK-677 supplementation may have positive effects on sleep. [62-67]
  7. Higher IGF-1 levels are also linked with better sleep, suggesting that MK-677 supplementation may have beneficial effects. [68-78]
  8. Studies on rats showed that growth hormone secretagogue administration activated sleep-regulatory neurons in the brain. [79]
  9. In obese patients, growth hormone secretagogue administration improved stage 2 sleep by reversing GH deficiency. [80-81]

D. Improves Cognitive Function

Doctors usually prescribe Ibutamoren (MK 677) for patients suffering from cognitive impairment because of its nootropic benefits. Nootropics are drugs, supplements, and other substances that have the ability to improve certain aspects of cognitive function such as learning, memory, creativity, and motivation. Several high-quality clinical studies support the beneficial effects of MK-677 on various cognitive functions and overall brain health:

  1. By increasing REM sleep duration and sleep quality, MK-677 can help improve cognitive function. [82-83]
  2. In older adults, the administration of growth hormone secretagogues improved short-term memory and active problem-solving skills, suggesting that MK-677 may also exert beneficial effects on cognitive function. [84]
  3. In adults with mild cognitive impairment and healthy older adults, 20 weeks of growth hormone secretagogue administration improved executive function and verbal memory. [85]
  4. MK-677 has also been found to improve various aspects of cognitive function by increasing IGF-1 levels. [86-90]
  5. With increased IGF-1 levels, the body activates intracellular pathways involved in the protection of nerve cells in the brain. [91-108]
  6. MK-677 also protects brain cells against programmed cell death (apoptosis) by increasing ghrelin levels, which in turn prevents cognitive decline. [109-114]
  7. MK-677 improves cognitive function and prevents age-related cognitive decline by increasing the levels of GH. [115-129]
  8. The administration of growth hormone secretagogues improves cognitive function by increasing the levels of brain chemicals such as gamma-Aminobutyric acid and N-acetyl-aspartyl-glutamate. [130]
  9. In healthy older adults, the administration of growth hormone secretagogues helped combat age-related cognitive decline and Alzheimer’s disease. [131]
  10. In rat models of Alzheimer’s disease, MK-677 administration reduced the formation of abnormal proteins known as amyloid beta (causative agent of AD). [132]
  11. SARMs such as MK-677 stimulate the growth and development of brain tissues, enhance communication of nerve cells (neurons), and promote brain cell survival. [133-136]

E. Accelerates Wound Healing and Tissue Regeneration

Growth hormone secretagogues such as Ibutamoren (MK 677) have the ability to accelerate the repair of damaged tissues caused by physical trauma or sports-related injuries. There is compelling evidence supporting the regenerative properties of MK-677:

  1. By boosting GH levels, MK-677 accelerates the migration of cells into the injured or damaged tissues, thus speeding up the wound healing process. [137-139]
  2. MK-677 can also speed up the wound healing process by increasing skin thickness. [140]
  3. MK-677 speeds up wound healing by increasing wound collagen content, granulation tissue, and wound tensile strength. [141-143]
  4. MK-677 increases IGF-1 levels, which in turn stimulates wound healing by increasing cell proliferation and collagen synthesis. [144-147]
  5. In mice, SARMs administration prevented damage to the central nervous system and improved regeneration by reducing inflammatory substances. [148]
  6. In rats, growth hormone secretagogue administration improved functional recovery after various injuries by stimulating the formation of new neuronal cells. [149]
  7. In mice, the administration of growth hormone secretagogue enhanced the healing of skin wounds resulting from trauma, surgery, or disease. [150]

Discover the power of advanced Wound Healing Peptides to accelerate recovery and promote tissue regeneration. Explore our range of cutting-edge products designed to optimize the wound healing process and enhance your body’s natural healing mechanisms. Take the first step towards faster and more effective wound healing today.

F. Maintains a Healthy Heart

Heart disease ranks among the top in terms of mortality worldwide. Interestingly, Ibutamoren (MK 677) possesses potent cardioprotective properties that can help reduce the prevalence of heart disease and the rate of deaths associated with this condition. Recent research suggests that MK-677 and other growth hormone secretagogues can help preserve heart function through various important mechanisms:

  1. In obese patients, MK-677 treatment improved heart health by reducing low-density lipoprotein (bad cholesterol). [151]
  2. By increasing ghrelin levels, MK-677 prevents programmed cell death of cardiomyocytes (heart cells). [152-154]
  3. By increasing GH levels, MK-677 significantly reduces the risk of heart disease and related deaths. [155-164]
  4. By increasing IGF-1 levels, MK-677 also reduces the risk of heart disease and related deaths. [165-180]
  5. MK-677 and other growth hormone secretagogues protect against myocardial infarction by activating signaling pathways responsible for self-renewal and survival of cardiac cells. [181-188]
  6. MK-677 also induces cardiac repair after myocardial infarction. [189-191]
  7. In animal models, MK-677 and other growth hormone secretagogues stimulated the self-renewal of cardiac stem cells and promoted their survival. [192-195]
  8. In mice, growth hormone secretagogue administration restored the electrical activity of the heart. [196]
  9. In rats, growth hormone secretagogue administration protected against heart damage induced by reduced oxygen. [197-201]
  10. In mice, growth hormone secretagogue administration stimulated the formation of new cardiac tissues. [202]

G. Strengthens the Immune System

Ibutamoren (MK 677) and other growth hormone secretagogues have the ability to enhance the immune response. Research suggests that they play a role in the regulation of immune function through the following important mechanisms:

  1. In humans, growth hormone secretagogues modulate the immune function through stimulation of the GH/insulin-like growth factor-1 (IGF-I) axis. [203-206]
  2. In the elderly, both short- and long-term growth hormone secretagogue administration increased the numbers of lymphocytes, monocytes, B-cells, and T-cells. [207]
  3. Growth hormone secretagogues can also modulate the immune function through brain mechanisms involved in sleep regulation. [208]
  4. By increasing GH levels, MK-677 helps regulate T cell development, cytokine production, B cell development, antibody production, neutrophil adhesion, monocyte migration, and anti-apoptotic action. [209-210]
  5. By increasing GH levels, MK-677 also significantly lowers the risk of various diseases related to a compromised immune system. [211-222]
  6. By increasing IGF-1 levels, MK-677 also significantly lowers the risk of autoimmune diseases and other immune system-related disorders. [223-237]
  7. By boosting ghrelin levels, MK-677 strengthens the immune system by lowering inflammation. [238]
  8. In animal models, the administration of growth hormone secretagogues increased the numbers of CD2+ αβ T-cells, CD25+CD4+ cells, and CD4+CD45R+ cells in the immune system. [239-240]

H. Improves Sex Drive and Sexual Function

The ability of Ibutamoren (MK 677) to positively influence the levels of vital hormones such as GH and IGF-1 can help improve sex drive and sexual function. There is strong scientific evidence supporting the beneficial effects of MK-677 and other growth hormone secretagogues on the sexual health of both men and women:

  1. MK-677 indirectly improves sexual function by increasing GH and IGF-1 levels, which in turn boosts the levels of nitric oxide, a naturally occurring substance that induces harder and longer penile erections. [241-249]
  2. Another mechanism by which MK-677 improves libido is by increasing testosterone and estrogen levels, which are hormones that regulate sexual desire and sexual function. [250-251]
  3. By boosting ghrelin levels, MK-677 also helps improve sexual function. [252-255]
  4. A growing body of clinical evidence suggests that growth hormone deficiency is strongly linked with low libido and erectile dysfunction, suggesting that boosting GH levels through MK-677 supplementation may help ramp up sexual power. [256-264]
  5. Studies also showed that IGF-1 deficiency is strongly linked with low libido and erectile dysfunction, suggesting that MK-677 may have beneficial effects on sex drive and sexual function. [265-271]
  6. In healthy postmenopausal women, growth hormone secretagogue supplementation improved libido without any adverse side effects. [272]
  7. In age-advanced men and women, 4 months of growth hormone secretagogue supplementation improved general well-being and libido. [273]

I. Improves Blood Sugar Levels

Ibutamoren (MK 677) and other growth hormone secretagogues have potent anti-diabetic properties. There is compelling evidence supporting the ability of MK-677 to bring down elevated levels of blood sugar in diabetic patients and animal models:

  1. In diabetic patients, MK-677 administration improved the body’s response to the effects of insulin, which in turn lowers blood sugar levels. [274]
  2. In diabetic patients, MK-677 administration significantly reduced blood sugar levels by increasing GH secretion. [275]
  3. MK-677 boosts IGF-1 levels, which in turn lowers blood sugar levels. [276-287]
  4. MK-677 also boosts GH levels, which results in a significant reduction in blood sugar levels. [288-301]
  5. In diabetic rats, growth hormone secretagogue administration enhanced insulin secretion, which in turn lowered blood sugar levels. [302-303]
  6. In diabetic rats, pre-treatment with growth hormone secretagogue improved insulin secretion and insulin reserve. [304-308]

J. Improves Cholesterol Profile

Chronic elevation in cholesterol levels significantly increases one’s risk of stroke, heart disease, hypertension, and other deadly diseases. According to studies, one can greatly reduce their risk for these debilitating medical conditions by reducing cholesterol levels through Ibutamoren (MK 677) supplementation:

  1. In obese patients, MK-677 treatment reduced the levels of low-density lipoprotein, which is known as bad cholesterol. [309]
  2. In older men and women, growth hormone secretagogue administration significantly reduced total cholesterol levels. [310]
  3. In older adults, growth hormone secretagogue administration reduced low-density lipoprotein levels without any adverse side effects. [311]
  4. By increasing GH levels, MK-677 can help bring down elevated cholesterol levels. [312-321]
  5. By boosting IGF-1 levels, MK-677 can also help reduce low-density lipoprotein levels and increase high-density lipoprotein (good cholesterol). [322-331]
  6. In rats with abnormal cholesterol profiles, growth hormone secretagogue administration reduced cholesterol levels. [332]

Unlocking the Power of MK-677: How Nitrogen Balance Boosts Muscle Growth and Fat Loss

One of the significant benefits of MK-677 is that it promotes an increased nitrogen balance in the body. This refers to the balance between the amount of nitrogen taken in through dietary protein and the amount of nitrogen excreted from the body.

During a cutting phase, when someone is in a caloric deficit, there is an increased risk of muscle catabolism, where the body breaks down muscle tissue for energy. This process can hinder muscle growth and lead to a loss of muscle mass. However, MK-677’s ability to enhance nitrogen balance helps offset this diet-induced catabolism by preserving more muscle tissue.

When you have a positive nitrogen balance (more nitrogen retained than excreted), it signals an environment that promotes muscle growth and repair. By maintaining a positive nitrogen balance during cutting, MK-677 allows individuals to continue building muscle while simultaneously losing fat. This is considered a remarkable feat because typically, losing fat and gaining muscle are two separate and often challenging processes. However, with MK-677’s influence on nitrogen balance, it becomes more achievable to attain these goals simultaneously.

It is essential to note that individual responses to MK-677 can vary, and the effectiveness of this process depends on various factors, including diet, exercise, and overall health. If considering MK-677 or any other supplement, it’s crucial to consult with a healthcare professional to ensure it is safe and appropriate for individual circumstances.

Ibutamoren (MK 677) Side Effects

MK-677 side effects are very uncommon. There have been some side effects associated with the use of this drug wherein the patient had one of the issues listed below at some point while being on MK-677. However, these side effects weren’t confirmed to be associated with the treatment and could have been a coincidence and not related to the use of MK-677. Despite this, it was listed as a side effect associated with MK-677 even though these associated side effects are very uncommon.

Side effects associated with MK-677 may include the following:

  • Headaches
  • Increased appetite
  • Increased blood sugar levels
  • Increased insulin levels
  • Increased levels of the stress hormone cortisol
  • Sleepiness
  • Mild lower extremity edema
  • Muscle pain

Ibutamoren (MK 677) Dosage

The typical dosage of MK-677 is 10-25 mg per day. It is typically taken once per day, but some people may choose to split the dose into two or three smaller doses. It is important to start with a low dose and gradually increase it to find the best dosage for you.

There is no one-size-fits-all answer to the question of how much MK-677 you should take. The best way to determine the right dosage for you is to talk to your doctor or a qualified healthcare professional. They can help you assess your individual needs and recommend a dosage that is safe and effective for you.

Here are some things to keep in mind when determining your MK-677 dosage:

  • Your weight: The dosage of MK-677 may need to be adjusted based on your weight.
  • Your age: Older adults may need a lower dosage than younger adults.
  • Your health status: If you have any health conditions, such as diabetes or high blood pressure, you may need to start with a lower dosage and increase it more slowly.
  • Your goals: If you are taking MK-677 for muscle growth, you may need a higher dosage than if you are taking it for other purposes, such as increasing your appetite or improving your sleep.

MK-677 Before and After Results

About Dr. George Shanlikian

Dr. George Shanlikian, renowned as the world’s best hormone therapy doctor, possesses expertise in various medical domains. These include Bio-Identical Hormone Replacement Therapy, Peptide Replacement Therapy, Anti-Aging Medicine, Regenerative Medicine, Stress Management, Nutrition Consulting, Nutritional Supplement Consulting, and Exercise Consulting.

Reference

  1. Meyer RM, Burgos-Robles A, Liu E, Correia SS, Goosens KA. A ghrelin-growth hormone axis drives stress-induced vulnerability to enhanced fear. Molecular psychiatry. 2014;19(12):1284-1294. doi:10.1038/mp.2013.135.

     

     

  2. Sun Y, Wang P, Zheng H, Smith RG. Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proceedings of the National Academy of Sciences of the United States of America. 2004;101(13):4679-4684.
    doi:10.1073/pnas.0305930101. 

     

     

  3. Svensson J, Lönn L, Jansson JO, et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab. 1998;83(2):362-9.

     

     

  4. Welle S, Thornton C, Statt M, Mchenry B. Growth hormone increases muscle mass and strength but does not rejuvenate myofibrillar protein synthesis in healthy subjects over 60 years old. J Clin Endocrinol Metab. 1996;81(9):3239-43.

     

     

  5. Kim KR, Nam SY, Song YD, Lim SK, Lee HC, Huh KB. Low-dose growth hormone treatment with diet restriction accelerates body fat loss, exerts anabolic effect and improves growth hormone secretory dysfunction in obese adults. Horm Res. 1999;51(2):78-84.

     

     

  6. Welle S, Thornton C, Statt M, Mchenry B. Growth hormone increases muscle mass and strength but does not rejuvenate myofibrillar protein synthesis in healthy subjects over 60 years old. J Clin Endocrinol Metab. 1996;81(9):3239-43.

     

     

  7. Tavares ABW, Micmacher E, Biesek S, et al. Effects of Growth Hormone Administration on Muscle Strength in Men over 50 Years Old. International Journal of Endocrinology. 2013;2013:942030. doi:10.1155/2013/942030.

     

     

  8. Velloso CP. Regulation of muscle mass by growth hormone and IGF-I. British Journal of Pharmacology. 2008;154(3):557-568. doi:10.1038/bjp.2008.153.

     

     

  9. Weber MM. Effects of growth hormone on skeletal muscle. Horm Res. 2002;58 Suppl 3:43-8.

     

     

  10. Rennie M. Claims for the anabolic effects of growth hormone: a case of the Emperor’s new clothes? British Journal of Sports Medicine. 2003;37(2):100-105. doi:10.1136/bjsm.37.2.100.

     

     

  11. Johannsson G, Grimby G, Sunnerhagen KS, Bengtsson BA. Two years of growth hormone (GH) treatment increase isometric and isokinetic muscle strength in GH-deficient adults. J Clin Endocrinol Metab. 1997;82(9):2877-84.

     

     

  12. Harman SM, Blackman MR. The effects of growth hormone and sex steroid on lean body mass, fat mass, muscle strength, cardiovascular endurance and adverse events in healthy elderly women and men. Horm Res. 2003;60(Suppl 1):121-4.

     

     

  13. Norrelund H, Nair KS, Jorgensen JO, Christiansen JS, Moller N. The protein-retaining effects of growth hormone during fasting involve inhibition of muscle-protein breakdown. Diabetes. 2001;50(1):96-104.

     

     

  14. Adams GR.Insulin-like growth factorin muscle growth and its potential abuse by athletes. Western Journal of Medicine. 2001;175(1):7-9.

     

     

  15. Velloso CP. Regulation of muscle mass by growth hormone and IGF-I. British Journal of Pharmacology. 2008;154(3):557-568. doi:10.1038/bjp.2008.153.

     

     

  16. Christoffolete MA, Silva WJ, Ramos GV, et al. Muscle IGF-1-Induced Skeletal Muscle Hypertrophy Evokes Higher Insulin Sensitivity and Carbohydrate Use as Preferential Energy Substrate. BioMed Research International. 2015;2015:282984. doi:10.1155/2015/282984.

     

     

     

  17. Hamarneh SR, Murphy CA, Shih CW, et al. Relationship Between Serum IGF-1 and Skeletal Muscle IGF-1 mRNA Expression to Phosphocreatine Recovery After Exercise in Obese Men With Reduced GH. The Journal of Clinical Endocrinology and Metabolism. 2015;100(2):617-625.
    doi:10.1210/jc.2014-2711. doi:10.1210/jc.2014-2711. 

     

     

  18. Heszele MF, Price SR. Insulin-like growth factor I: the yin and yang of muscle atrophy. Endocrinology. 2004;145(11):4803-5.

     

     

  19. Shavlakadze T, Chai J, Maley K, et al. A growth stimulus is needed for IGF-1 to induce skeletal muscle hypertrophy in vivo. J Cell Sci. 2010;123(Pt 6):960-71.

     

     

  20. Zou Y, Dong Y, Meng Q, Zhao Y, Li N. Incorporation of a skeletal muscle-specific enhancer in the regulatory region of Igf1 upregulates IGF1 expression and induces skeletal muscle hypertrophy. Scientific Reports. 2018;8:2781. doi:10.1038/s41598-018-21122-5.

     

     

     

  21. Available athttps://eurapa.biomedcentral.com/articles/10.1007/s11556-007-0022-1#:~:text=IGF%2DI%20has%20been%20implicated%20in%20the%20loss%20of%20muscle,than%20noncarriers%20with%20strength%20training..

     

     

     

  22. Ye F, Mathur S, Liu M, et al. Overexpression of insulin-like growth factor-1 attenuates skeletal muscle damage and accelerates muscle regeneration and functional recovery after disuse. Exp Physiol. 2013;98(5):1038-52.

     

     

  23. Murphy MG, Plunkett LM, Gertz BJ, et al. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. J Clin Endocrinol Metab. 1998;83(2):320-5.

     

     

  24. Adunsky A, Chandler J, Heyden N, et al. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Arch Gerontol Geriatr. 2011;53(2):183-9.

     

     

  25. Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601-11.

     

     

  26. Chapman IM, Pescovitz OH, Murphy G, et al. Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults. J Clin Endocrinol Metab. 1997;82(10):3455-63.

     

     

     

  27. Svensson J, Ohlsson C, Jansson JO, et al. Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males. J Bone Miner Res. 1998;13(7):1158-66.

     

     

  28. Murphy MG, Bach MA, Plotkin D, et al. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group. J Bone Miner Res. 1999;14(7):1182-8.

     

     

     

  29. Murphy MG, Weiss S, Mcclung M, et al. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab.
    2001;86(3):1116-25. 

     

     

  30. Bach, M. A., Rockwood, K., Zetterberg, C., Thamsborg, G., Hébert, R., Devogelaer, J. P., Christiansen, J. S., Rizzoli, R., Ochsner, J. L., Beisaw, N., Gluck, O., Yu, L., Schwab, T., Farrington, J., Taylor, A. M., Ng, J., Fuh, V., & MK 0677 Hip Fracture
    Study Group (2004). The effects of MK-0677, an oral growth hormone secretagogue, in patients with hip fracture. Journal of the American Geriatrics Society, 52(4), 516–523.https://doi.org/10.1111/j.1532-5415.2004.52156.x.. 

     

     

     

  31. Devin, J. K., Vaughan, D. E., Blevins, L. S., Jr, Chen, Q., Covington, J., Verity, D. K., & Young, P. P. (2008). Low-dose growth hormone administration mobilizes endothelial progenitor cells in healthy adults. Growth hormone & IGF research : official
    journal of the Growth Hormone Research Society and the International IGF Research Society, 18(3), 253–263.https://doi.org/10.1016/j.ghir.2007.11.001.. 

     

     

  32. Eriksen EF, Kassem M, Langdahl B. Growth hormone, insulin-like growth factors and bone remodelling. Eur J Clin Invest. 1996;26(7):525-34.

     

     

  33. Ohlsson C, Bengtsson BA, Isaksson OG, Andreassen TT, Slootweg MC. Growth hormone and bone. Endocr Rev. 1998;19(1):55-79.

     

     

  34. Olney RC. Regulation of bone mass by growth hormone. Med Pediatr Oncol. 2003;41(3):228-34.

     

     

  35. Bex M, Bouillon R. Growth hormone and bone health. Horm Res. 2003;60 Suppl 3:80-6.

     

     

  36. Tritos NA, Klibanski A. Effects of Growth Hormone on Bone. Prog Mol Biol Transl Sci. 2016;138:193-211.

     

     

  37. Kuzma M, Payer J. [Growth hormone deficiency, its influence on bone mineral density and risk of osteoporotic fractures]. Cas Lek Cesk. 2010;149(5):211-6.

     

     

  38. Lindsey RC, Mohan S. Skeletal Effects of Growth Hormone and Insulin-like Growth Factor-I Therapy. Molecular and cellular endocrinology. 2016;432:44-55. doi:10.1016/j.mce.2015.09.017.

     

     

  39. Bouillon R. Growth hormone and bone. Horm Res. 1991;36 Suppl 1:49-55.

     

     

  40. Capozzi A, Casa SD, Altieri B, Pontecorvi A. Low bone mineral density in a growth hormone deficient (GHD) adolescent. Clinical Cases in Mineral and Bone Metabolism. 2013;10(3):203-205.

     

     

  41. Gillberg P, Mallmin H, Petrén-mallmin M, Ljunghall S, Nilsson AG. Two years of treatment with recombinant human growth hormone increases bone mineral density in men with idiopathic osteoporosis. J Clin Endocrinol Metab. 2002;87(11):4900-6.

     

     

  42. Aloia JF, Zanzi I, Ellis K, et al. Effects of growth hormone in osteoporosis. J Clin Endocrinol Metab. 1976;43(5):992-9.

     

     

  43. Colao A, Di somma C, Pivonello R, et al. Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism. J Clin Endocrinol Metab. 1999;84(6):1919-24.

     

     

  44. Krantz E, Trimpou P, Landin-wilhelmsen K. Effect of Growth Hormone Treatment on Fractures and Quality of Life in Postmenopausal Osteoporosis: A 10-Year Follow-Up Study. J Clin Endocrinol Metab. 2015;100(9):3251-9.

     

     

  45. Fall C, Hindmarsh P, Dennison E, Kellingray S, Barker D, Cooper C. Programming of growth hormone secretion and bone mineral density in elderly men: a hypothesis. J Clin Endocrinol Metab. 1998;83(1):135-9.

     

     

  46. Rosen CJ. IGF-I and osteoporosis. Clin Lab Med. 2000;20(3):591-602.

     

     

  47. Kawai M, Rosen CJ. The Insulin-Like Growth Factor System in Bone: Basic and Clinical Implications. Endocrinology and metabolism clinics of North America. 2012;41(2):323-vi. doi:10.1016/j.ecl.2012.04.013.

     

     

  48. Niu T, Rosen CJ. The insulin-like growth factor-I gene and osteoporosis: a critical appraisal. Gene. 2005;361:38-56.

     

     

  49. Chen Y-C, Zhang L, Li E-N, et al. Association of the insulin-like growth factor-1 single nucleotide polymorphisms rs35767, rs2288377, and rs5742612 with osteoporosis risk: A meta-analysis. Pany. S, ed. Medicine. 2017;96(51):e9231. doi:10.1097/MD.0000000000009231.

     

     

     

  50. Vittorio Locatelli and Vittorio E. Bianchi, “Effect of GH/IGF-1 on Bone Metabolism and Osteoporsosis,” International Journal of Endocrinology, vol. 2014, Article ID 235060, 25 pages, 2014.https://doi.org/10.1155/2014/235060

     

     

     

  51. Kurland ES, Rosen CJ, Cosman F, et al. Insulin-like growth factor-I in men with idiopathic osteoporosis. J Clin Endocrinol Metab. 1997;82(9):2799-805.

     

     

  52. Sroga GE, Wu PC, Vashishth D. Insulin-like growth factor 1, glycation and bone fragility: implications for fracture resistance of bone. PLoS ONE. 2015;10(1):e0117046.

     

     

  53. Vandenput L, Sjögren K, Svensson J, Ohlsson C. The Role of IGF-1 for Fracture Risk in Men. Frontiers in Endocrinology. 2012;3:51. doi:10.3389/fendo.2012.00051.

     

     

  54. Ertuğrul I, Karan MA, Karan A, et al. Relationship between insulin-like growth factor 1 and bone mineral density in men aged over 65 years. Med Princ Pract. 2003;12(4):231-6.

     

     

  55. Gao S, Lv Z, Zhou C, Mao C, Sheng W. Association between IGF-1 polymorphisms and risk of osteoporosis in Chinese population: a meta-analysis. BMC Musculoskeletal Disorders. 2018;19:141. doi:10.1186/s12891-018-2066-y.

     

     

  56. Liu JM, Zhao HY, Ning G, et al. IGF-1 as an early marker for low bone mass or osteoporosis in premenopausal and postmenopausal women. J Bone Miner Metab. 2008;26(2):159-64.

     

     

  57. Copinschi G, Leproult R, Van onderbergen A, et al. Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology. 1997;66(4):278-86.

     

     

  58. Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults: A Randomized, Controlled Trial. Annals of internal medicine. 2008;149(9):601-611.

     

     

  59. Frieboes RM, Murck H, Maier P, Schier T, Holsboer F, Steiger A. Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man. Neuroendocrinology. 1995;61(5):584-9.

     

     

  60. Moreno-Reyes R, Kerkhofs M, L’hermite-balériaux M, Thorner MO, Van Cauter E, Copinschi G. Evidence against a role for the growth hormone-releasing peptide axis in human slow-wave sleep regulation. Am J Physiol. 1998;274(5 Pt 1): E779-84.

     

     

  61. Frieboes RM, Murck H, Antonijevic IA, Steiger A. Effects of growth hormone-releasing peptide-6 on the nocturnal secretion of GH, ACTH and cortisol and on the sleep EEG in man: role of routes of administration. J Neuroendocrinol. 1999;11(6):473-8.

     

     

     

  62. Morselli LL, Nedeltcheva A, Leproult R, et al. Impact of growth hormone replacement therapy on sleep in adult patients with growth hormone deficiency of pituitary origin. European journal of endocrinology/European Federation of Endocrine Societies. 2013;168(5):10.1530/EJE-12-1037.
    doi:10.1530/EJE-12-1037. 

     

     

  63. Haqq AM, Stadler DD, Jackson RH, Rosenfeld RG, Purnell JQ, Lafranchi SH. Effects of growth hormone on pulmonary function, sleep quality, behavior, cognition, growth velocity, body composition, and resting energy expenditure in Prader-Willi syndrome. J
    Clin Endocrinol Metab. 2003;88(5):2206-12. 

     

     

  64. Van cauter E, Copinschi G. Interrelationships between growth hormone and sleep. Growth Horm IGF Res. 2000;10 Suppl B:S57-62.

     

     

  65. Copinschi G, Nedeltcheva A, Leproult R, et al. Sleep disturbances, daytime sleepiness, and quality of life in adults with growth hormone deficiency. J Clin Endocrinol Metab. 2010;95(5):2195-202.

     

     

  66. Davidson JR, Moldofsky H, Lue FA. Growth hormone and cortisol secretion in relation to sleep and wakefulness. Journal of Psychiatry and Neuroscience. 1991;16(2):96-102.

     

     

  67. Moreno-reyes R, Kerkhofs M, L’hermite-balériaux M, Thorner MO, Van cauter E, Copinschi G. Evidence against a role for the growth hormone-releasing peptide axis in human slow-wave sleep regulation. Am J Physiol. 1998;274(5 Pt 1):E779-84.

     

     

  68. Shah N, Rice T, Tracy D, et al. Sleep and Insulin-Like Growth Factors in the Cardiovascular Health Study. Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine. 2013;9(12):1245-1251. doi:10.5664/jcsm.3260.

     

     

     

  69. Mysliwiec V, Gill J, Matsangas P, Baxter T, Barr T, Roth BJ. IGF-1: a potential biomarker for efficacy of sleep improvement with automatic airway pressure therapy for obstructive sleep apnea?. Sleep Breath. 2015;19(4):1221-8.

     

     

  70. Izumi S, Ribeiro-filho FF, Carneiro G, Togeiro SM, Tufik S, Zanella MT. IGF-1 Levels are Inversely Associated With Metabolic Syndrome in Obstructive Sleep Apnea. J Clin Sleep Med. 2016;12(4):487-93.

     

     

  71. Izumi S, Ribeiro-Filho FF, Carneiro G, Togeiro SM, Tufik S, Zanella MT. IGF-1 Levels are Inversely Associated With Metabolic Syndrome in Obstructive Sleep Apnea. Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy
    of Sleep Medicine. 2016;12(4):487-493. doi:10.5664/jcsm.5672. 

     

     

  72. Rusch HL, Gill JM. Effect of Acute Sleep Disturbance and Recovery on Insulin-Like Growth Factor-1 (IGF-1): Possible Connections and Clinical Implications. Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep
    Medicine. 2015;11(10):1245-1246. doi:10.5664/jcsm.5108. 

     

     

  73. Prinz PN, Moe KE, Dulberg EM, et al. Higher plasma IGF-1 levels are associated with increased delta sleep in healthy older men. J Gerontol A Biol Sci Med Sci. 1995;50(4):M222-6.

     

     

  74. Damanti S, Bourron O, Doulazmi M, et al. Relationship between sleep parameters, insulin resistance and age-adjusted insulin like growth factor-1 score in non diabetic older patients. Blondeau B, ed. PLoS ONE. 2017;12(4):e0174876. doi:10.1371/journal.pone.0174876.

     

     

     

  75. Obál F, Kapás L, Gardi J, Taishi P, Bodosi B, Krueger JM. Insulin-like growth factor-1 (IGF-1)-induced inhibition of growth hormone secretion is associated with sleep suppression. Brain Res. 1999;818(2):267-74.

     

     

  76. Chennaoui M, Drogou C, Sauvet F, Gomez-merino D, Scofield DE, Nindl BC. Effect of acute sleep deprivation and recovery on Insulin-like Growth Factor-I responses and inflammatory gene expression in healthy men. Eur Cytokine Netw. 2014;25(3):52-7.

     

     

  77. Rasmussen MH, Wildschiødtz G, Juul A, Hilsted J. Polysomnographic sleep, growth hormone insulin-like growth factor-I axis, leptin, and weight loss. Obesity (Silver Spring). 2008;16(7):1516-21.

     

     

  78. Levada OA, Troyan AS. Insulin-like growth factor-1: a possible marker for emotional and cognitive disturbances, and treatment effectiveness in major depressive disorder. Annals of General Psychiatry. 2017;16:38. doi:10.1186/s12991-017-0161-3.

     

     

  79. Peterfi Z, McGinty D, Sarai E, Szymusiak R. Growth hormone-releasing hormone activates sleep regulatory neurons of the rat preoptic hypothalamus. American Journal of Physiology – Regulatory, Integrative and Comparative Physiology. 2010;298(1):R147-R156.
    doi:10.1152/ajpregu.00494.2009. 

     

     

  80. Cordido F, Peñalva A, Dieguez C, Casanueva FF. Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity. J Clin Endocrinol
    Metab. 1993;76(4):819-23. 

     

     

  81. Cordido F, Peñalva A, Peino R, Casanueva FF, Dieguez C. Effect of combined administration of growth hormone (GH)-releasing hormone, GH-releasing peptide-6, and pyridostigmine in normal and obese subjects. Metab Clin Exp. 1995;44(6):745-8.

     

     

  82. Copinschi G, Leproult R, Van onderbergen A, et al. Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology. 1997;66(4):278-86.

     

     

  83. Diekelmann S. Sleep for cognitive enhancement. Frontiers in Systems Neuroscience. 2014;8:46. doi:10.3389/fnsys.2014.00046.

     

     

  84. Aleman A, Verhaar HJ, De haan EH, et al. Insulin-like growth factor-I and cognitive function in healthy older men. J Clin Endocrinol Metab. 1999;84(2):471-5.

     

     

  85. Baker LD, Barsness SM, Borson S, et al. Effects of Growth Hormone–Releasing Hormone on Cognitive Function in Adults With Mild Cognitive Impairment and Healthy Older Adults: Results of a Controlled Trial. Archives of neurology. 2012;69(11):1420-1429. doi:10.1001/archneurol.2012.1970.

     

     

     

  86. Alvarez A, Cacabelos R, Sanpedro C, García-Fantini M, Aleixandre M. Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer’s disease. Neurobiol Aging. 2007;28(4):533–536.

     

     

  87. Luppi C, Fioravanti M, Bertolini B, et al. Growth factors decrease in subjects with mild to moderate Alzheimer’s disease (AD): potential correction with dehydroepiandrosterone-sulfate (DHEAS) Arch Gerontol Geriatr. 2009;49(suppl 1):173–184.

     

     

  88. Aleman A, Torres-Alemán I. Circulating insulin-like growth factor I and cognitive function: neuromodulation throughout the lifespan. Prog Neurobiol. 2009;89(3):256–265.

     

     

  89. van Dam PS, Aleman A. Insulin-like growth factor-I, cognition and brain aging. Eur J Pharmacol. 2004;490(1–3):87–95.

     

     

  90. Rollero A, Murialdo G, Fonzi S, et al. Relationship between cognitive function, growth hormone and insulin-like growth factor I plasma levels in aged subjects. Neuropsychobiology. 1998;38(2):73–79.

     

     

  91. Frago LM, Pañeda C, Dickson SL, Hewson AK, Argente J, Chowen JA. Growth hormone (GH) and GH-releasing peptide-6 increase brain insulin-like growth factor-I expression and activate intracellular signalling pathways involved in neuroprotection. Endocrinology.
    2002;143(10):4113-22. 

     

     

  92. Baserga R, Hongo A, Rubini M, Prisco M, Valentini SB 1997 The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta 1332:F105–F126.

     

     

  93. Kulik G, Klippel A, Weber MJ 1997 Antiapoptotic signaling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase and Akt. Mol Cell Biol 17:1595–1606.

     

     

  94. Chrysis D, Calikoglu AS, Ye P, D’Ercole AJ 2001 Insulin-like growth factor-I overexpression attenuates cerebellar apoptosis by altering the expression of Bcl family proteins in a developmentally specific manner. J Neurosci 21:1481–1489.

     

     

  95. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, Hemmings BA 1996 Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 15:6541–6551.

     

     

  96. Dudek H, Datta SR, Franke TF, Birnbaum MJ, Yao R, Cooper GM, Segal RA, Kaplan DR, Greenberg ME 1997 Regulation of neural survival by the serine-threonine protein kinase Akt. Science 275:661–668.

     

     

  97. Mehrhof FB, Muller FU, Bergmann MW, Li P, Wang Y, Schmitz W, Dietz R, von Harsdorf R 2001 In cardiomyocyte hypoxia, insulin-like growth factor-I-induced antiapoptotic signaling requires phosphatidylinositol-3-OH-kinase-dependent and mitogen-activated
    protein kinase-dependent activation of the transcription factor cAMP response element-binding protein. Circulation 104:2088–2094 

     

     

  98. Gleichmann M, Weller M, Schuyltz JB 2000 Insulin-like growth factor-1-mediated protection from neuronal apoptosis is linked to phosphorylation of the pro-apoptotic protein BAD but not to inhibition of cytochrome c translocation in rat cerebellar neurons.
    Neurosci Lett 282:69–72 

     

     

  99. Peruzzi F, Prisco M, Dews M, Salomoni P, Grassilli E, Romano G, Calabretta B, Baserga R 1999 Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol 19:7203–7215.

     

     

  100. Kulik G, Weber MJ 1998 Akt-dependent and -independent survival signaling pathways utilized by insulin-like growth factor I. Mol Cell Biol 18:6711–6718.

     

     

  101. Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ 2001 p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci USA 98:9666–9670.

     

     

  102. Desbois-Moutho C, Cadoret A, Blivet-Van Eggelpoel MJ, Bertrand F, Cherqui G, Perret C, Capeau J 2001 Insulin and IGF-1 stimulate the β-catenin pathway through two signalling cascades involving GSK-3β inhibition and Ras activation. Oncogene 20:252–259

     

     

     

  103. Park BC, Kido Y, Accili D 1999 Differential signaling of insulin and IGF-1 receptors to glycogen synthesis in murine hepatocytes. Biochemistry 38:7517–7523

     

     

  104. Cui H, Meng Y, Bulleit RF 1998 Inhibition of glycogen synthase kinase 3β activity regulates proliferation of cultured cerebellar granule cells. Brain Res Dev Brain Res 111:177–188.

     

     

  105. Tamatani M, Ogawa S, Nuñez G, Tokyama M 1998 Growth factors prevent changes in Bcl-2 and Bax expression and neuronal apoptosis induced by nitric oxide. Cell Death Differ 5:911–919

     

     

  106. Baker NlL, Carlo Russo V, Bernard O, D’Ercole AJ, Werther GA 1999 Interactions between bcl-2 and the IGF-I system control apoptosis in the developing mouse brain. Brain Res Dev Brain Res 118:109–118.

     

     

  107. Du K, Montminy M 1998 CREB is a regulatory target for the protein kinase Akt/PKB. J Biol Chem 273:32377.

     

     

  108. Pugazhenthi S, Nesterova A, Sable C, Heidenreich KA, Boxer LM, Heasly LE, Reusch JE 2000 Akt/protein kinase B upregulates Bcl-2 expression through cAMP-response element-binding protein. J Biol Chem 275:10761–10766.

     

     

  109. Kim SW, Her SJ, Park SJ, et al. Ghrelin stimulates proliferation and differentiation and inhibits apoptosis in osteoblastic MC3T3-E1 cells. Bone. 2005;37(3):359-69.

     

     

  110. Kim YS, Choi DH, Block ML, et al. A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration via microglial activation. FASEB J. 2007;21(1):179-87.

     

     

  111. Banks WA, Tschöp M, Robinson SM, Heiman ML. Extent and direction of ghrelin transport across the blood-brain barrier is determined by its unique primary structure. J Pharmacol Exp Ther. 2002;302(2):822-7.

     

     

  112. Chung H, Seo S, Moon M, Park S. Phosphatidylinositol-3-kinase/Akt/glycogen synthase kinase-3 beta and ERK1/2 pathways mediate protective effects of acylated and unacylated ghrelin against oxygen-glucose deprivation-induced apoptosis in primary rat cortical
    neuronal cells. J Endocrinol. 2008;198(3):511-21. 

     

     

  113. García-cáceres C, Lechuga-sancho A, Argente J, Frago LM, Chowen JA. Death of hypothalamic astrocytes in poorly controlled diabetic rats is associated with nuclear translocation of apoptosis inducing factor. J Neuroendocrinol. 2008;20(12):1348-60

     

     

  114. Frago LM, Pañeda C, Dickson SL, Hewson AK, Argente J, Chowen JA. Growth hormone (GH) and GH-releasing peptide-6 increase brain insulin-like growth factor-I expression and activate intracellular signaling pathways involved in neuroprotection. Endocrinology.
    2002;143(10):4113-22. 

     

     

  115. Nyberg F, Hallberg M. Growth hormone and cognitive function. Nat Rev Endocrinol. 2013;9(6):357-65.

     

     

  116. Baker LD, Barsness SM, Borson S, et al. Effects of Growth Hormone–Releasing Hormone on Cognitive Function in Adults With Mild Cognitive Impairment and Healthy Older Adults: Results of a Controlled Trial. Archives of neurology. 2012;69(11):1420-1429. doi:10.1001/archneurol.2012.1970.

     

     

     

  117. Maruff P, Falleti M. Cognitive function in growth hormone deficiency and growth hormone replacement. Horm Res. 2005;64 Suppl 3:100-8.

     

     

  118. Baker LD, Barsness SM, Borson S, et al. Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-9.

     

     

  119. Ong LK, Chow WZ, Tebay C, et al. Growth Hormone Improves Cognitive Function After Experimental Stroke. Stroke. 2018;49(5):1257-1266.

     

     

  120. Bove RM, White CC, Gerweck AV, et al. Effect of growth hormone on cognitive function in young women with abdominal obesity. Clinical endocrinology. 2016;84(4):635-637. doi:10.1111/cen.12996.

     

     

  121. Aleman A, Verhaar HJ, De haan EH, et al. Insulin-like growth factor-I and cognitive function in healthy older men. J Clin Endocrinol Metab. 1999;84(2):471-5.

     

     

  122. Sonntag WE, Deak F, Ashpole N, et al. Insulin-like growth factor-1 in CNS and cerebrovascular aging. Frontiers in Aging Neuroscience. 2013;5:27. doi:10.3389/fnagi.2013.00027.

     

     

  123. Nashiro K, Guevara-aguirre J, Braskie MN, et al. Brain Structure and Function Associated with Younger Adults in Growth Hormone Receptor-Deficient Humans. J Neurosci. 2017;37(7):1696-1707.

     

     

  124. Available at https://journals.lww.com/neurotodayonline/fulltext/2012/09200/Can_a_Growth_Hormone_Stimulating_Drug_Improve.6.aspx.

     

     

  125. Available at http://pediatrics.aappublications.org/content/142/4/e20173938.

     

     

  126. High WM, Briones-Galang M, Clark JA, et al. Effect of Growth Hormone Replacement Therapy on Cognition after Traumatic Brain Injury. Journal of Neurotrauma. 2010;27(9):1565-1575. doi:10.1089/neu.2009.1253.

     

     

  127. Grugni G, Sartorio A, Crinò A. Growth hormone therapy for Prader–willi syndrome: challenges and solutions. Therapeutics and Clinical Risk Management. 2016;12:873-881. doi:10.2147/TCRM.S70068.

     

     

  128. Xue Y, Gao Y, Wang S, Wang P. An examination of the effects of different doses of recombinant human growth hormone on children with growth hormone deficiency. Experimental and Therapeutic Medicine. 2016;11(5):1647-1652. doi:10.3892/etm.2016.3091.

     

     

     

  129. Lupien SB, Bluhm EJ, Ishii DN. Systemic insulin-like growth factor-I administration prevents cognitive impairment in diabetic rats, and brain IGF regulates learning/memory in normal adult rats. J Neurosci Res. 2003;74(4):512-23.

     

     

  130. Friedman SD, Baker LD, Borson S, et al. Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging. JAMA Neurol. 2013;70(7):883-90.

     

     

  131. Vitiello MV, Moe KE, Merriam GR, Mazzoni G, Buchner DH, Schwartz RS. Growth hormone releasing hormone improves the cognition of healthy older adults. Neurobiol Aging. 2006;27(2):318-23.

     

     

  132. Jeong YO, Shin SJ, Park JY, et al. MK-0677, a Ghrelin Agonist, Alleviates Amyloid Beta-Related Pathology in 5XFAD Mice, an Animal Model of Alzheimer’s Disease. Int J Mol Sci. 2018;19(6)

     

     

  133. Bajetto A, Barbero S, Bonavia R, et al. Stromal cell-derived factor-1α induces astrocyte proliferation through the activation of extracellular signal-regulated kinases 1/2 pathway. J Neurochem. 2001;77:1226–1236.

     

     

  134. Qui MS, Green SH. PC12 cell neuronal differentiation is associated with prolonged p21ras activity and consequent prolonged ERK activity. Neuron. 1992;9:705–717.

     

     

  135. Krapivinsky G, Krapivinsky L, Manasian Y, et al. The NMDA receptor is coupled to the ERK pathway by a direct interaction between NR2B and RasGRF1. Neuron. 2003;40:775–784.

     

     

  136. Alonso M, Viola H, Izquierdo I, Medina JH. Aversive experiences are associated with rapid and transient activation of ERKs in the rat hippocampus. Neurobiol Learn Mem. 2002;77:119–124.

     

     

  137. Raschke M, Kolbeck S, Bail H. Homologous growth hormone accelerates healing of segmental bone defects. Bone. 2001;4:368–373.

     

     

  138. Lal S, Wolf S, Herndon D. Growth hormone, burns and tissue healing. Growth Horm IGF Res. 2002;10:39–43.

     

     

  139. Ghofrani A, Holler D, Shulmann K. The influence of systemic growth hormone administration on the healing time of skin graft donor sites in a pig model. Plast Reconstr Surg. 1999;104:470–475.

     

     

  140. Mulligan K, Tai V, Schambelan M. Use of growth hormone and other anabolic agents in AIDS wasting. JPEN J Parenter Enteral Nutr. 1999;23:S202–S209.

     

     

  141. Pierre E, Perez-Polo J, Mitchell A. Insulin-like growth factor-1 liposomal gene transfer and systemic growth hormone stimulate wound healing. J Burn Care Rehabil. 1997;4:287–289.

     

     

  142. Biolo G, Fleming R, Wolfe R. Physiological hyperinsulinemia stimulates protein synthesis and enhances the transport of selected amino acids in human skeletal muscle. J Clin Invest. 1995;95:811–817.

     

     

  143. Zhang X, Chinkes D, Irtun O, Wolfe R. Anabolic insulin action on skin wound protein is augmented by exogenesis amino acids. Am J Physiol Endocrinol Metab. 2002;282:308–315.

     

     

  144. Coerper S, Wolf S, von Kiparski S, et al. Insulin-like growth factor accelerates gastric ulcer healing by stimulating cell proliferation and inhibiting gastric acid secretion. Scand J Gastroenterol. 2001;36:921–992.

     

     

  145. Lin E, Goncalves JA, Lowry SF. Efficacy of nutritional pharmacology in surgical patients. Curr Opin Clin Nutr Metab Care. 1998;1:41–50.

     

     

  146. Lieberman S, Bukar J, Chen S. Effects of recombinant human insulin-like growth in cachectic patients with the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1994;78:404–410.

     

     

  147. Blumenfield I, Saiiyi S, Lanir Y. Enhancement of bone defect healing in old rats by TGF beta and IGF-1. Exp Gerontol. 2002;37:53–55.

     

     

  148. Hou YJ, Banerjee R, Thomas B, et al. SARM is required for neuronal injury and cytokine production in response to central nervous system viral infection. J Immunol. 2013;191(2):875-83.

     

     

  149. Johansson I, Destefanis S, Aberg ND, et al. Proliferative and protective effects of growth hormone secretagogues on adult rat hippocampal progenitor cells. Endocrinology. 2008;149(5):2191-9.

     

     

  150. Dioufa N, Schally AV, Chatzistamou I, et al. Acceleration of wound healing by growth hormone-releasing hormone and its agonists. Proc Natl Acad Sci USA. 2010;107(43):18611-5.

     

     

  151. Svensson J, Jansson JO, Ottosson M, et al. Treatment of obese subjects with the oral growth hormone secretagogue MK-677 affects serum concentrations of several lipoproteins, but not lipoprotein(a). J Clin Endocrinol Metab. 1999;84(6):2028-33.

     

     

  152. Baldanzi G, Filigheddu N, Cutrupi S, et al. Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. The Journal of Cell Biology. 2002;159(6):1029-1037. doi:10.1083/jcb.200207165.

     

     

     

  153. ateishi K, et al. (2007) Human cardiac stem cells exhibit mesenchymal features and are maintained through Akt/GSK-3beta signaling. Biochem Biophys Res Commun 352(3):635–641.

     

     

  154. Choi SH, et al. (2013) Regulation of ROS-independent ERK signaling rescues replicative cellular senescence in ex vivo expanded human c-kit-positive cardiac progenitor cells. Int J Cardiol 169(1):73–82.

     

     

  155. Available at https://academic.oup.com/jcem/article/90/3/1864/2837042.

     

     

  156. Isgaard J. Cardiovascular disease and risk factors: the role of growth hormone. Horm Res. 2004;62 Suppl 4:31-8.

     

     

  157. Lombardi G, Colao A, Ferone D, et al. Effect of growth hormone on cardiac function. Horm Res. 1997;48 Suppl 4:38-42.

     

     

  158. Isgaard J, Arcopinto M, Karason K, Cittadini A. GH and the cardiovascular system: an update on a topic at heart. Endocrine. 2015;48(1):25-35. doi:10.1007/s12020-014-0327-6.

     

     

  159. Saccà L, Cittadini A, Fazio S. Growth hormone and the heart. Endocr Rev. 1994;15(5):555-73.

     

     

  160. Arcopinto M, Salzano A, Giallauria F, et al. Growth Hormone Deficiency Is Associated with Worse Cardiac Function, Physical Performance, and Outcome in Chronic Heart Failure: Insights from the T.O.S.CA. GHD Study. PLoS ONE. 2017;12(1):e0170058.

     

     

  161. De leonibus C, De marco S, Stevens A, Clayton P, Chiarelli F, Mohn A. Growth Hormone Deficiency in Prepubertal Children: Predictive Markers of Cardiovascular Disease. Horm Res Paediatr. 2016;85(6):363-71.

     

     

  162. Available at https://clinicaltrials.gov/ct2/show/NCT00397319.

     

     

  163. Liang S, Xue J, Li G. Effects of recombinant human growth hormone administration on cardiovascular risk factors in obese children with relative growth hormone deficiency. Lipids Health Dis. 2018;17(1):66.

     

     

  164. Available at https://link.springer.com/article/10.1007/s12020-016-1206-0.

     

     

  165. Ungvari Z, Csiszar A. The Emerging Role of IGF-1 Deficiency in Cardiovascular Aging: Recent Advances. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2012;67A(6):599-610. doi:10.1093/gerona/gls072.

     

     

  166. Andreassen M, Raymond I, Kistorp C, Hildebrandt P, Faber J, Kristensen LØ. IGF1 as predictor of all cause mortality and cardiovascular disease in an elderly population. Eur J Endocrinol. 2009;160(1):25-31.

     

     

  167. Kaplan RC, Strickler HD, Rohan TE, Muzumdar R, Brown DL. Insulin-like growth factors and coronary heart disease. Cardiol Rev. 2005;13(1):35-9.

     

     

  168. Castellano G, Affuso F, Conza PD, Fazio S. The GH/IGF-1 Axis and Heart Failure. Current Cardiology Reviews. 2009;5(3):203-215. doi:10.2174/157340309788970306.

     

     

  169. Abdulle AM, Gillett MP, Abouchacra S, et al. Low IGF-1 levels are associated with cardiovascular risk factors in haemodialysis patients. Mol Cell Biochem. 2007;302(1-2):195-201.

     

     

  170. Córdova C, Boullosa DA, Custódio MR, et al. Atheroprotective Properties of Serum IGF-1 in the Carotid and Coronary Territories and Beneficial Role on the Physical Fitness of the Oldest Old. J Gerontol A Biol Sci Med Sci. 2016;71(10):1281-8.

     

     

  171. Wallander M, Norhammar A, Malmberg K, Ohrvik J, Rydén L, Brismar K. IGF binding protein 1 predicts cardiovascular morbidity and mortality in patients with acute myocardial infarction and type 2 diabetes. Diabetes Care. 2007;30(9):2343-8.

     

     

  172. Shah N, Rice T, Tracy D, et al. Sleep and Insulin-Like Growth Factors in the Cardiovascular Health Study. Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine. 2013;9(12):1245-1251. doi:10.5664/jcsm.3260.

     

     

     

  173. González-guerra JL, Castilla-cortazar I, Aguirre GA, et al. Partial IGF-1 deficiency is sufficient to reduce heart contractibility, angiotensin II sensibility, and alter gene expression of structural and functional cardiac proteins. PLoS ONE. 2017;12(8):e0181760.

     

     

     

  174. Chigogora S, Zaninotto P, Kivimaki M, Steptoe A, Batty GD. Insulin-like growth factor 1 and risk of depression in older people: the English Longitudinal Study of Ageing. Transl Psychiatry. 2016;6(9):e898.

     

     

  175. Barton JS, Hindmarsh PC, Preece MA. Serum insulin-like growth factor 1 in congenital heart disease. Arch Dis Child. 1996;75(2):162-3.

     

     

  176. Giovannini S, Cesari M, Marzetti E, Leeuwenburgh C, Maggio M, Pahor M. EFFECTS OF ACE-INHIBITION ON IGF-1 AND IGFBP-3 CONCENTRATIONS IN OLDER ADULTS WITH HIGH CARDIOVASCULAR RISK PROFILE. The journal of nutrition, health & aging. 2010;14(6):457-460.

     

     

     

  177. Strazhesko ID, Tkacheva ON, Akasheva DU, et al. Growth Hormone, Insulin-Like Growth Factor-1, Insulin Resistance, and Leukocyte Telomere Length as Determinants of Arterial Aging in Subjects Free of Cardiovascular Diseases. Front Genet. 2017;8:198.

     

     

     

  178. Bergman D, Halje M, Nordin M, Engström W. Insulin-like growth factor 2 in development and disease: a mini-review. Gerontology. 2013;59(3):240-9.

     

     

  179. Touvron M, Escoubet B, Mericskay M, et al. Locally expressed IGF1 propeptide improves mouse heart function in induced dilated cardiomyopathy by blocking myocardial fibrosis and SRF-dependent CTGF induction. Dis Model Mech. 2012;5(4):481-91.

     

     

  180. Milman S, Atzmon G, Huffman DM, et al. Low insulin-like growth factor-1 level predicts survival in humans with exceptional longevity. Aging Cell. 2014;13(4):769-71.

     

     

  181. Zhang Z, et al. (2013) Rosuvastatin enhances the therapeutic efficacy of adipose-derived mesenchymal stem cells for myocardial infarction via PI3K/Akt and MEK/ERK pathways. Basic Res Cardiol 108(2):333.

     

     

  182. Sun X, Fang B, Zhao X, Zhang G, Ma H (2014) Preconditioning of mesenchymal stem cells by sevoflurane to improve their therapeutic potential. PLoS ONE 9(3):e90667.

     

     

  183. Gude N, et al. (2006) Akt promotes increased cardiomyocyte cycling and expansion of the cardiac progenitor cell population. Circ Res 99(4):381–388.

     

     

  184. Hahn JY, et al. (2008) Pre-treatment of mesenchymal stem cells with a combination of growth factors enhances gap junction formation, cytoprotective effect on cardiomyocytes, and therapeutic efficacy for myocardial infarction. J Am Coll Cardiol 51(9):933–943.

     

     

     

  185. Pasha Z, et al. (2008) Preconditioning enhances cell survival and differentiation of stem cells during transplantation in infarcted myocardium. Cardiovasc Res 77(1):134–142.

     

     

  186. Gude N, et al. (2006) Akt promotes increased cardiomyocyte cycling and expansion of the cardiac progenitor cell population. Circ Res 99(4):381–388.

     

     

  187. Kanashiro-Takeuchi RM, Schulman IH, Hare JM (2011) Pharmacologic and genetic strategies to enhance cell therapy for cardiac regeneration. J Mol Cell Cardiol 51(4):619–625.

     

     

  188. Fischer KM, et al. (2009) Enhancement of myocardial regeneration through genetic engineering of cardiac progenitor cells expressing Pim-1 kinase. Circulation 120(21):2077–2087.

     

     

  189. Kiaris H, Schally AV, Kalofoutis A (2005) Extrapituitary effects of the growth hormone-releasing hormone. Vitam Horm 70:1–24.

     

     

  190. Ciampani T, Fabbri A, Isidori A, Dufau ML (1992) Growth hormone-releasing hormone is produced by rat Leydig cell in culture and acts as a positive regulator of Leydig cell function. Endocrinology 131:2785–2792.

     

     

  191. Khorram O, Garthwaite M, Golos T (2001) The influence of aging and sex hormones on expression of growth hormone-releasing hormone in the human immune system. J Clin Endocrinol Metab 86:3157–3161.

     

     

  192. Florea V, Majid SS, Kanashiro-takeuchi RM, et al. Agonists of growth hormone-releasing hormone stimulate self-renewal of cardiac stem cells and promote their survival. Proc Natl Acad Sci USA. 2014;111(48):17260-5.

     

     

  193. Kanashiro-Takeuchi RM, et al. (2010) Cardioprotective effects of growth hormone-releasing hormone agonist after myocardial infarction. Proc Natl Acad Sci USA 107(6):2604–2609.

     

     

  194. Kanashiro-Takeuchi RM, et al. (2012) Activation of growth hormone releasing hormone (GHRH) receptor stimulates cardiac reverse remodeling after myocardial infarction (MI). Proc Natl Acad Sci USA 109(2):559–563.

     

     

  195. Cai R, et al. (2014) Synthesis of new potent agonistic analogs of growth hormone-releasing hormone (GHRH) and evaluation of their endocrine and cardiac activities. Peptides 52:104–112.

     

     

  196. Ma Y, Zhang L, Launikonis BS, Chen C. Growth hormone secretagogues preserve the electrophysiological properties of mouse cardiomyocytes isolated from in vitro ischemia/reperfusion heart. Endocrinology. 2012;153(11):5480-90.

     

     

  197. Frascarelli S, Ghelardoni S, Ronca-Testoni S, Zucchi R 2003 Effect of ghrelin and synthetic growth hormone secretagogues in normal and ischemic rat heart. Basic Res Cardiol 98:401–405.

     

     

  198. Chang L, Ren Y, Liu X, Li WG, Yang J, Geng B, Weintraub NL, Tang C 2004 Protective effects of ghrelin on ischemia/reperfusion injury in the isolated rat heart. J Cardiovasc Pharmacol 43:165–170.

     

     

  199. Zhang GG, Teng X, Liu Y, Cai Y, Zhou YB, Duan XH, Song JQ, Shi Y, Tang CS, Yin XH, Qi YF 2009 Inhibition of endoplasm reticulum stress by ghrelin protects against ischemia/reperfusion injury in rat heart. Peptides 30:1109–1116.

     

     

  200. Torsello A, Bresciani E, Rossoni G, Avallone R, Tulipano G, Cocchi D, Bulgarelli I, Deghenghi R, Berti F, Locatelli V 2003 Ghrelin plays a minor role in the physiological control of cardiac function in the rat. Endocrinology 144:1787–1792.

     

     

  201. Cittadini A, Grossman JD, Strömer H, Katz SE, Morgan JP, Douglas PS. Importance of an intact growth hormone/insulin-like growth factor 1 axis for normal post-infarction healing: studies in dwarf rats. Endocrinology. 2001;142(1):332-8.

     

     

  202. Waters MJ, Blackmore DG (2011) Growth hormone (GH), brain development and neural stem cells. Pediatr Endocrinol Rev 9(2):549–553.

     

     

  203. Khorram, M. Garthwaite, T. Golos. The influence of aging and sex hormones on expression of growth hormone-releasing hormone in the human immune system. J. Clin. Endocrinol. Metab., 86 (2001), pp. 3157-3161.

     

     

  204. Dialynas, H. Brown-Borg, A. Bartke. Immune function in transgenic mice overexpressing growth hormone (GH) releasing hormone, GH or GH antagonist. Proc. Soc. Exp. Biol. Med., 221 (1999), pp. 178-183.

     

     

  205. Dorshkind, N.D. Horseman. Anterior pituitary hormones, stress, and immune system homeostasis. Bioessays, 23 (2001), pp. 288-294.

     

     

  206. Burgess, et al. The immune–endocrine loop during aging: role of growth hormone and insulin-like growth factor-I. Neuroimmunomodulation, 6 (1999), pp. 56-68.

     

     

  208. C. Gelato. Aging and immune function: a possible role for growth hormone. Horm. Res., 45 (1996), pp. 46-49.

     

     

  209. L. Marshall, B. Perras, H.L. Fehm, J. Born. Changes in immune cell counts and interleukin (IL)-1beta production in humans after a somnogenically active growth hormone-releasing hormone (GHRH) administration. Brain Behav. Immun., 15 (2001), pp. 227-234.

     

     

     

  210. Hattori N. Expression, regulation and biological actions of growth hormone (GH) and ghrelin in the immune system. Growth Horm IGF Res. 2009;19(3):187-97.

     

     

  211. Masternak MM, Bartke A. Growth hormone, inflammation and aging. Pathobiology of Aging & Age Related Diseases. 2012;2:10.3402/pba.v2i0.17293. doi:10.3402/pba.v2i0.17293.

     

     

  212. Meazza C, Pagani S, Travaglino P, Bozzola M. Effect of growth hormone (GH) on the immune system. Pediatr Endocrinol Rev. 2004;1 Suppl 3:490-5.

     

     

  213. Rapaport R, Oleske J, Ahdieh H, Solomon S, Delfaus C, Denny T. Suppression of immune function in growth hormone-deficient children during treatment with human growth hormone. J Pediatr. 1986;109(3):434-9.

     

     

  214. Koo GC, Huang C, Camacho R, et al. Immune enhancing effect of a growth hormone secretagogue. J Immunol. 2001;166(6):4195-201.

     

     

  215. Morrhaye G, Kermani H, Legros J-J, et al. Impact of Growth Hormone (GH) Deficiency and GH Replacement upon Thymus Function in Adult Patients. Unutmaz D, ed. PLoS ONE. 2009;4(5):e5668. doi:10.1371/journal.pone.0005668.

     

     

  216. Gelato MC. Aging and immune function: a possible role for growth hormone. Horm Res. 1996;45(1-2):46-9.

     

     

  217. Available at https://www.nature.com/articles/pr1984567.

     

     

  218. Available at https://clinicaltrials.gov/ct2/show/NCT00071240.

     

     

  219. Alzaid A, Kim JH, Devlin RH, Martin SAM, Macqueen DJ. Growth hormone transgenesis in coho salmon disrupts muscle immune function impacting cross-talk with growth systems. J Exp Biol. 2018;221(Pt 13).

     

     

  220. Carroll PV, Christ ER, Bengtsson BA, et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. J Clin Endocrinol Metab. 1998;83(2):382-95.

     

     

  221. Available at http://www.asja.eg.net/article.asp?issn=1687-7934;year=2016;volume=9;issue=2;spage=194;epage=200;aulast=Salem.

     

     

  222. Villares R, Kakabadse D, Juarranz Y, Gomariz RP, Martínez-a C, Mellado M. Growth hormone prevents the development of autoimmune diabetes. Proc Natl Acad Sci USA. 2013;110(48):E4619-27.

     

     

  223. Mazzoccoli G, Vendemiale G, De Cata A, Carughi S, Tarquini R. Altered time structure of neuro-endocrine-immune system function in lung cancer patients. BMC Cancer. 2010;10:314. doi:10.1186/1471-2407-10-314.

     

     

  224. Smith TJ. Insulin-Like Growth Factor-I Regulation of Immune Function: A Potential Therapeutic Target in Autoimmune Diseases? Pharmacological Reviews. 2010;62(2):199-236. doi:10.1124/pr.109.002469.

     

     

  225. Ge R-T, Mo L-H, Wu R, et al. Insulin-like growth factor-1 endues monocytes with immune suppressive ability to inhibit inflammation in the intestine. Scientific Reports. 2015;5:7735. doi:10.1038/srep07735.

     

     

  226. Bilbao D, Luciani L, Johannesson B, Piszczek A, Rosenthal N. Insulin-like growth factor-1 stimulates regulatory T cells and suppresses autoimmune disease. EMBO Molecular Medicine. 2014;6(11):1423-1435. doi:10.15252/emmm.201303376.

     

     

  227. Franz A-C, Faass O, Köllner B, et al. Endocrine and Local IGF-I in the Bony Fish Immune System. Dixon B, ed. Biology. 2016;5(1):9. doi:10.3390/biology5010009.

     

     

  228. Spadaro O, Camell C, Bosurgi L, et al. IGF1 shapes the macrophage activation in response to immunometabolic challenge. Cell reports. 2017;19(2):225-234. doi:10.1016/j.celrep.2017.03.046.

     

     

  229. Alzaid A, Castro R, Wang T, et al. Cross Talk Between Growth and Immunity: Coupling of the IGF Axis to Conserved Cytokine Pathways in Rainbow Trout. Endocrinology. 2016;157(5):1942-55.

     

     

  230. Rodrigues LS, Hacker MA, Illarramendi X, et al. Circulating levels of insulin-like growth factor-I (IGF-I) correlate with disease status in leprosy. BMC Infect Dis. 2011;11:339.

     

     

  231. Gelato MC. Aging and immune function: a possible role for growth hormone. Horm Res. 1996;45(1-2):46-9.

     

     

  232. Van bilsen K, Driessen GJ, De paus RA, et al. Low level IGF-1 and common variable immune deficiency: an unusual combination. Neth J Med. 2008;66(9):368-72.

     

     

  233. Rodrigues LS, Hacker MA, Illarramendi X, et al. Circulating levels of insulin-like growth factor-I (IGF-I) correlate with disease status in leprosy. BMC Infectious Diseases. 2011;11:339. doi:10.1186/1471-2334-11-339.

     

     

  234. Ge RT, Mo LH, Wu R, et al. Insulin-like growth factor-1 endues monocytes with immune suppressive ability to inhibit inflammation in the intestine. Sci Rep. 2015;5:7735.

     

     

  235. Puche JE, Castilla-Cortázar I. Human conditions of insulin-like growth factor-I (IGF-I) deficiency. Journal of Translational Medicine. 2012;10:224. doi:10.1186/1479-5876-10-224.

     

     

  236. Quentien MH, Delemer B, Papadimitriou DT, et al. Deficit in anterior pituitary function and variable immune deficiency (DAVID) in children presenting with adrenocorticotropin deficiency and severe infections. J Clin Endocrinol Metab. 2012;97(1):E121-8.

     

     

     

  237. Available at https://www.tandfonline.com/doi/abs/10.1586/eem.10.73.

     

     

  238. Tu W, Cheung PT, Lau YL. Insulin-like growth factor 1 promotes cord blood T cell maturation and inhibits its spontaneous and phytohemagglutinin-induced apoptosis through different mechanisms. J Immunol. 2000;165(3):1331-6

     

     

  239. Baatar D, Patel K, Taub DD. The effects of ghrelin on inflammation and the immune system. Mol Cell Endocrinol. 2011;340(1):44-58.

     

     

  240. Brown PA, Davis WC, Draghia-akli R. Immune-enhancing effects of growth hormone-releasing hormone delivered by plasmid injection and electroporation. Mol Ther. 2004;10(4):644-51.

     

     

  241. Available at https://www.researchgate.net/publication/326998293_Biological_activity_of_a_new_Growth_hormone_secretagogue_study_in_fish_and_murine_cell_line.

     

     

  242. Rubinek T, Rubinfeld H, Hadani M, Barkai G, Shimon I. Nitric oxide stimulates growth hormone secretion from human fetal pituitaries and cultured pituitary adenomas. Endocrine. 2005;28(2):209-16.

     

     

  243. Valverde I, Peñalva A, Ghigo E, Casanueva FF, Dieguez C. Involvement of nitric oxide in the regulation of growth hormone secretion in dogs. Neuroendocrinology. 2001;74(4):213-9.

     

     

  244. Rigamonti AE, Cella SG, Marazzi N, Müller EE. Nitric oxide modulation of the growth hormone-releasing activity of Hexarelin in young and old dogs. Metab Clin Exp. 1999;48(2):176-82.

     

     

  245. Doi SQ, Jacot TA, Sellitti DF, et al. Growth hormone increases inducible nitric oxide synthase expression in mesangial cells. J Am Soc Nephrol. 2000;11(8):1419-25.

     

     

  246. Available at http://erj.ersjournals.com/content/31/4/815.

     

     

  247. Deniz Tuncel, Fatma Inanc Tolun, and Ismail Toru, “Serum Insulin-Like Growth Factor-1 and Nitric Oxide Levels in Parkinson’s Disease,” Mediators of Inflammation, vol. 2009, Article ID 132464, 4 pages, 2009.

     

     

  248. Available at https://clinicaltrials.gov/ct2/show/NCT00470002.

     

     

  249. Böger RH , Skamira C , Bode-Böger SM , Brabant G , von zur Muhlen A , Frolich JC. 1996. Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. A double-blind, placebo-controlled
    study. J Clin Invest 98:2706–2713. 

     

     

  250. Thum T , Fleissner F , Klink I , Tsikas D , Jakob M , Bauersachs J , Stichtenoth DO. 2007. Growth hormone treatment improves markers of systemic nitric oxide bioavailability via insulin-like growth factor-I. J Clin Endocrinol Metab 92:4172–4179.

     

     

     

  251. Mani maran RR, Sivakumar R, Ravisankar B, et al. Growth hormone directly stimulates testosterone and oestradiol secretion by rat Leydig cells in vitro and modulates the effects of LH and T3. Endocr J. 2000;47(2):111-8.

     

     

  252. Ho KY, Evans WS, Blizzard RM, et al. Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab. 1987;64(1):51-8.

     

     

  253. Amitani M, Amitani H, Cheng K-C, et al. The Role of Ghrelin and Ghrelin Signaling in Aging. International Journal of Molecular Sciences. 2017;18(7):1511. doi:10.3390/ijms18071511.

     

     

  254. Minor RK, Chang JW, de Cabo R. Hungry for Life: How the arcuate nucleus and neuropeptide Y may play a critical role in mediating the benefits of calorie restriction. Molecular and cellular endocrinology. 2009;299(1):79-88. doi:10.1016/j.mce.2008.10.044.

     

     

     

  255. Babaei-Balderlou F, Khazali H. Effects of Ghrelin on Sexual Behavior and Luteinizing Hormone Beta-subunit Gene Expression in Male Rats . Journal of Reproduction & Infertility. 2016;17(2):88-96.

     

     

  256. https://www.sciencedaily.com/releases/2015/01/150127110955.htm.

     

     

  257. Brod M, Pohlman B, Højbjerre L, Adalsteinsson JE, Rasmussen MH. Impact of adult growth hormone deficiency on daily functioning and well-being. BMC Research Notes. 2014;7:813. doi:10.1186/1756-0500-7-813.

     

     

  258. Maggi M, Buvat J, Corona G, Guay A, Torres LO. Hormonal causes of male sexual dysfunctions and their management (hyperprolactinemia,thyroid disorders, GH disorders, and DHEA). J Sex Med. 2013;10(3):661-77.

     

     

     

  259. Ginzburg E, Lin A, Sigler M, Olsen D, Klimas N, Mintz A. Testosterone and growth hormone normalization: a retrospective study of health outcomes. Journal of multidisciplinary healthcare. 2008;1:79-86.

     

     

  260. Brod M, Højbjerre L, Adalsteinsson JE, Rasmussen MH. Assessing the impact of growth hormone deficiency and treatment in adults: development of a new disease-specific measure. J Clin Endocrinol Metab. 2014;99(4):1204-12.

     

     

  261. Available at https://www.researchgate.net/publication/12600670_Effects_of_growth_hormone_on_male_reproductive_functions.

     

     

  262. Galdiero M, Pivonello R, Grasso LF, Cozzolino A, Colao A. Growth hormone, prolactin, and sexuality. J Endocrinol Invest. 2012;35(8):782-94.

     

     

  263. Becker AJ, Uckert S, Stief CG, et al. Possible role of human growth hormone in penile erection. J Urol. 2000;164(6):2138-42.

     

     

  264. Becker AJ, Uckert S, Stief CG, et al. Serum levels of human growth hormone during different penile conditions in the cavernous and systemic blood of healthy men and patients with erectile dysfunction. Urology. 2002;59(4):609-14.

     

     

  265. Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997;82(5):1472-9.Gades NM, Jacobson DJ, McGree ME, et al. The associations between serum sex hormones, erectile function, and sex drive: the Olmsted County study of urinary symptoms and health status among men. The journal of sexual medicine. 2008;5(9):2209-2220. doi:10.1111/j.1743-6109.2008.00924.x.

     

     

     

  266. Otunctemur A, Ozbek E, Sahin S, et al. Low serum insulin-like growth factor-1 in patients with erectile dysfunction. Basic and Clinical Andrology. 2016;26:1. doi:10.1186/s12610-015-0028-x.

     

     

  267. Rajfer J. Growth Factors and Gene Therapy for Erectile Dysfunction. Reviews in Urology. 2000;2(1):34.

     

     

  268. Pastuszak AW, Liu JS, Vij A. IGF-1 levels are significantly correlated with patient-reported measures of sexual function. International journal of impotence research. 2011; 23(5):220-6.

     

     

  269. Pastuszak AW, Liu JS, Vij A, et al. IGF-1 levels are significantly correlated with patient-reported measures of sexual function. Int J Impot Res. 2011;23(5):220-6.

     

     

  270. El-Sakka AI, Lin CS, Chui RM, Dahiya R, Lue TF. Effects of diabetes on nitric oxide synthase and growth factor genes and protein expression in an animal model. Int J Impot Res. 1999;11:123–32. doi: 10.1038/sj.ijir.3900392.

     

     

  271. Soh J, Katsuyama M, Ushijima S, Mizutani Y, Kawauchi A, Yabe-Nishimura C, et al. Localization of increased insulin-like growth factor binding protein-3 in diabetic rat penis: Implications for erectile dysfunction. Urology. 2007;70:1019–23. doi: 10.1016/j.urology.2007.07.057.

     

     

     

  272. Pu XY, Zheng XG, Zhang Y, Xiao HJ, Xu ZP, Liu JM, et al. Higher expression of mRNA and protein of insulin-like growth factor binding protein-3 in old rat penile tissues: implications for erectile dysfunction. J Sex Med. 2011;8:2181–90. doi: 10.1111/j.1743-6109.2011.02318.x.

     

     

     

  273. Veldhuis JD, Erickson D, Wigham J, Weist S, Miles JM, Bowers CY. Gender, Sex-Steroid, and Secretagogue-Selective Recovery from Growth Hormone-Induced Feedback in Older Women and Men. The Journal of Clinical Endocrinology and Metabolism. 2011;96(8):2540-2547.
    doi:10.1210/jc.2011-0298. 

    You can read the full article at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3146792/

     

  274. Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997;82(5):1472-9.

     

     

  275. Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601-11.

     

     

  276. Catalina PF, Mallo F, Andrade MA, García-mayor RV, Diéguez C. Growth hormone (GH) response to GH-releasing peptide-6 in type 1 diabetic patients with exaggerated GH-releasing hormone-stimulated GH secretion. J Clin Endocrinol Metab. 1998;83(10):3663-7.

     

     

     

  277. Jacks T, Smith R, Judith F, et al. MK-0677, a potent, novel, orally active growth hormone (GH) secretagogue: GH, insulin-like growth factor I, and other hormonal responses in beagles. Endocrinology. 1996;137(12):5284-9.

     

     

  278. Hickey GJ, Jacks TM, Schleim KD, et al. Repeat administration of the GH secretagogue MK-0677 increases and maintains elevated IGF-I levels in beagles. J Endocrinol. 1997;152(2):183-92.

     

     

  279. Schleim KD, Jacks T, Cunningham P, et al. Increases in circulating insulin-like growth factor I levels by the oral growth hormone secretagogue MK-0677 in the beagle are dependent upon pituitary mediation. Endocrinology. 1999;140(4):1552-8.

     

     

  280. Teppala S, Shankar A. Association Between Serum IGF-1 and Diabetes Among U.S. Adults. Diabetes Care. 2010;33(10):2257-2259. doi:10.2337/dc10-0770.

     

     

  281. Simpson HL, Umpleby AM, Russell-jones DL. Insulin-like growth factor-I and diabetes. A review. Growth Horm IGF Res. 1998;8(2):83-95.

     

     

  282. Friedrich N, Thuesen B, Jørgensen T, et al. The association between IGF-I and insulin resistance: a general population study in Danish adults. Diabetes Care. 2012;35(4):768-73.

     

     

  283. Palta M, LeCaire T, Sadek-Badawi M, Herrera V, Danielson KK. The trajectory of IGF-1 across age and duration of type 1 diabetes. Diabetes/metabolism research and reviews. 2014;30(8):777-783. doi:10.1002/dmrr.2554.

    You can read the full article at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236234/

     

  284. Aguirre GA, De Ita JR, de la Garza RG, Castilla-Cortazar I. Insulin-like growth factor-1 deficiency and metabolic syndrome. Journal of Translational Medicine. 2016;14:3. doi:10.1186/s12967-015-0762-z.

     

     

  285. Drogan D, Schulze MB, Boeing H, Pischon T. Insulin-Like Growth Factor 1 and Insulin-Like Growth Factor-Binding Protein 3 in Relation to the Risk of Type 2 Diabetes Mellitus: Results From the EPIC-Potsdam Study. Am J Epidemiol. 2016;183(6):553-60.

     

     

     

  286. Suda K, Matsumoto R, Fukuoka H, et al. The influence of type 2 diabetes on serum GH and IGF-I levels in hospitalized Japanese patients. Growth Horm IGF Res. 2016;29:4-10.

     

     

  287. Færch L, Juul A, Pedersen-Bjergaard U, Thorsteinsson B. Association of IGF1 with glycemic control and occurrence of severe hypoglycemia in patients with type 1 diabetes mellitus. Endocrine Connections. 2012;1(1):31-36. doi:10.1530/EC-12-0012.

     

     

     

  288. Chantelau E. Evidence that upregulation of serum IGF-1 concentration can trigger acceleration of diabetic retinopathy. Br J Ophthalmol. 1998;82(7):725-30.

     

     

  289. Fridlyand LE, Tamarina NA, Schally AV, Philipson LH. Growth Hormone-Releasing Hormone in Diabetes. Frontiers in Endocrinology. 2016;7:129. doi:10.3389/fendo.2016.00129.

     

     

  290. Johansen PB, Segev Y, Landau D, Phillip M, Flyvbjerg A. Growth hormone (GH) hypersecretion and GH receptor resistance in streptozotocin diabetic mice in response to a GH secretagogue. Exp Diabesity Res. 2003;4(2):73-81.

     

     

  291. Clark RG, Thomas GB, Mortensen DL, et al. Growth hormone secretagogues stimulate the hypothalamic-pituitary-adrenal axis and are diabetogenic in the Zucker diabetic fatty rat. Endocrinology. 1997;138(10):4316-23.

     

     

  292. Holly JM, Amiel SA, Sandhu RR, Rees LH, Wass JA. The role of growth hormone in diabetes mellitus. J Endocrinol. 1988;118(3):353-64.

     

     

  293. Nazaimoon WM, Ng ML, Khalid BA. Fasting growth hormone levels in diabetes mellitus. Ann Acad Med Singap. 1993;22(6):861-3.

     

     

  294. Wurzburger MI, Prelevic GM, Sonksen PH, Balint-peric L. Growth hormone levels in patients with type 1 diabetes are age related. Diabet Med. 1993;10(2):159-61.

     

     

  295. Kim S-H, Park M-J. Effects of growth hormone on glucose metabolism and insulin resistance in human. Annals of Pediatric Endocrinology & Metabolism. 2017;22(3):145-152. doi:10.6065/apem.2017.22.3.145.

     

     

  296. Luger A, Mattsson AF, Koltowska-häggström M, et al. Incidence of diabetes mellitus and evolution of glucose parameters in growth hormone-deficient subjects during growth hormone replacement therapy: a long-term observational study. Diabetes Care.
    2012;35(1):57-62. 

     

     

  297. Del guercio MJ, Di natale B, Gargantini L, Garlaschi C, Chiumello G. Effect of somatostatin on blood sugar, plasma growth hormone, and glucagon levels in diabetic children. Diabetes. 1976;25(7):550-3.

     

     

  298. Bonfig W, Molz K, Woelfle J, et al. Metabolic safety of growth hormone in type 1 diabetes and idiopathic growth hormone deficiency. J Pediatr. 2013;163(4):1095-8.e4.

     

     

  299. Jeffcoate W. Growth hormone therapy and its relationship to insulin resistance, glucose intolerance and diabetes mellitus: a review of recent evidence. Drug Saf. 2002;25(3):199-212.

     

     

  300. Nambam B, Schatz D. Growth hormone and insulin-like growth factor-I axis in type 1 diabetes. Growth Horm IGF Res. 2018;38:49-52.

     

     

  301. Attanasio AF, Jung H, Mo D, et al. Prevalence and incidence of diabetes mellitus in adult patients on growth hormone replacement for growth hormone deficiency: a surveillance database analysis. J Clin Endocrinol Metab. 2011;96(7):2255-61.

     

     

  302. Bonfig W, Lindberg A, Carlsson M, et al. Efficacy of Growth Hormone Treatment in Children with Type 1 Diabetes Mellitus and Growth Hormone Deficiency-An Analysis of KIGS Data. J Pediatr. 2018;198:260-264.

     

     

  303. Granado M, García-cáceres C, Tuda M, Frago LM, Chowen JA, Argente J. Insulin and growth hormone-releasing peptide-6 (GHRP-6) have differential beneficial effects on cell turnover in the pituitary, hypothalamus and cerebellum of streptozotocin (STZ)-induced
    diabetic rats. Mol Cell Endocrinol. 2011;337(1-2):101-13. 

     

     

  304. Bailey CJ, Wilkes LC, Flatt PR, Conlon JM, Buchanan KD. Effects of growth hormone-releasing hormone on the secretion of islet hormones and on glucose homeostasis in lean and genetically obese-diabetic (ob/ob) mice and normal rats. J Endocrinol (1989)
    123(1):19–24.10.1677/joe.0.1230019. 

     

     

  305. Ludwig B, Ziegler CG, Schally AV, Richter C, Steffen A, Jabs N, et al. Agonist of growth hormone-releasing hormone as a potential effector for survival and proliferation of pancreatic islets. Proc Natl Acad Sci U S A (2010) 107(28):12623–8.10.1073/pnas.1005098107.

     

     

     

  306. Ludwig B, Rotem A, Schmid J, Weir GC, Colton CK, Brendel MD, et al. Improvement of islet function in a bioartificial pancreas by enhanced oxygen supply and growth hormone releasing hormone agonist. Proc Natl Acad Sci U S A (2012) 109(13):5022–7.10.1073/pnas.1201868109.

     

     

     

  307. Zhang X, Cui T, He J, Wang H, Cai R, Popovics P, et al. Beneficial effects of growth hormone-releasing hormone agonists on rat INS-1 cells and on streptozotocin-induced NOD/SCID mice. Proc Natl Acad Sci U S A (2015) 112(44):13651–6.10.1073/pnas.1518540112.

     

     

     

  308. Schubert U, Schmid J, Lehmann S, Zhang XY, Morawietz H, Block NL, et al. Transplantation of pancreatic islets to adrenal gland is promoted by agonists of growth-hormone-releasing hormone. Proc Natl Acad Sci U S A (2013) 110(6):2288–93.10.1073/pnas.1221505110.

     

     

     

  309. Schmid J, Ludwig B, Schally AV, Steffen A, Ziegler CG, Block NL, et al. Modulation of pancreatic islets-stress axis by hypothalamic releasing hormones and 11beta-hydroxysteroid dehydrogenase. Proc Natl Acad Sci U S A (2011) 108(33):13722–7.10.1073/pnas.1110965108.

     

     

     

  310. Svensson J, Jansson JO, Ottosson M, et al. Treatment of obese subjects with the oral growth hormone secretagogue MK-677 affects serum concentrations of several lipoproteins, but not lipoprotein(a). J Clin Endocrinol Metab. 1999;84(6):2028-33.

     

     

     

  311. Hersch EC, Merriam GR. Growth hormone (GH)–releasing hormone and GH secretagogues in normal aging: Fountain of Youth or Pool of Tantalus? Clinical Interventions in Aging. 2008;3(1):121-129.

     

     

  312. Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53.

     

     

  313. O’neal DN, Hew FL, Best JD, Alford F. The effect of 24 months recombinant human growth hormone (rh-GH) on LDL cholesterol, triglyceride-rich lipoproteins and apo [a] in hypopituitary adults previously treated with conventional replacement therapy. Growth Horm IGF Res. 1999;9(3):165-73.

     

     

  314. Leese GP, Wallymahmed M, Vanheyningen C, Tames F, Wieringa G, Macfarlane IA. HDL-cholesterol reductions associated with adult growth hormone replacement. Clin Endocrinol (Oxf). 1998;49(5):673-7.

     

     

  315. Gács G, Romics L. Effect of growth hormone on serum lipoproteins in growth hormone deficiency. Exp Clin Endocrinol. 1987;90(2):227-31.

     

     

  316. Leonsson M, Oscarsson J, Bosaeus I, et al. Growth hormone (GH) therapy in GH-deficient adults influences the response to a dietary load of cholesterol and saturated fat in terms of cholesterol synthesis, but not serum low density lipoprotein cholesterol levels. J Clin Endocrinol Metab. 1999;84(4):1296-303.

     

     

  317. Zhu WF, Tang SJ, Shen Z, Wang YM, Liang L. Growth hormone reverses dyslipidemia in adult offspring after maternal undernutrition. Sci Rep. 2017;7(1):6038.

     

     

  318. Chen M, Gan D, Luo Y, et al. Effect of recombinant human growth hormone therapy on blood lipid and carotid intima-media thickness in children with growth hormone deficiency. Pediatr Res. 2018;83(5):954-960.

     

     

  319. Tonstad S, Sundt E, Ose L, et al. The effect of growth hormone on low-density lipoprotein cholesterol and lipoprotein (a) levels in familial hypercholesterolemia. Metab Clin Exp. 1996;45(11):1415-21.

     

     

  320. Gács G, Romics L. Effect of growth hormone on serum lipoproteins in growth hormone deficiency. Exp Clin Endocrinol. 1987;90(2):227-31.

     

     

  321. Beentjes JA, Van tol A, Sluiter WJ, Dullaart RP. Effect of growth hormone replacement therapy on plasma lecithin:cholesterol acyltransferase and lipid transfer protein activities in growth hormone-deficient adults. J Lipid Res. 2000;41(6):925-32.

     

     

     

  322. Xu L, Xu C, Yu C, et al. Association between serum growth hormone levels and nonalcoholic fatty liver disease: a cross-sectional study. PLoS ONE. 2012;7(8):e44136.

     

     

  323. Succurro E, Arturi F, Grembiale A, et al. Positive association between plasma IGF1 and high-density lipoprotein cholesterol levels in adult nondiabetic subjects. Eur J Endocrinol. 2010;163(1):75-80.

     

     

  324. Burchardt P, Tabaczewski P, Goździcka-józefiak A, et al. Association between insulin like growth factor-1 and lipoprotein metabolism in stable angina patients on statin therapy: a pilot study. Kardiol Pol. 2012;70(10):1017-22.

     

     

  325. Liang S, Hu Y, Liu C, Qi J, Li G. Low insulin-like growth factor 1 is associated with low high-density lipoprotein cholesterol and metabolic syndrome in Chinese nondiabetic obese children and adolescents: a cross-sectional study. Lipids in Health and Disease. 2016;15:112. doi:10.1186/s12944-016-0275-7.

     

     

  326. Eggert ML, Wallaschofski H, Grotevendt A, et al. Cross-sectional and longitudinal relation of IGF1 and IGF-binding protein 3 with lipid metabolism. Eur J Endocrinol. 2014;171(1):9-19.

     

     

  327. Arturi F, Succurro E, Procopio C, et al. Nonalcoholic fatty liver disease is associated with low circulating levels of insulin-like growth factor-I. J Clin Endocrinol Metab. 2011;96(10):E1640-4.

     

     

  328. Izumi S, Ribeiro-filho FF, Carneiro G, Togeiro SM, Tufik S, Zanella MT. IGF-1 Levels are Inversely Associated With Metabolic Syndrome in Obstructive Sleep Apnea. J Clin Sleep Med. 2016;12(4):487-93.

     

     

  329. Wang WC, Chiu YF, Chung RH, et al. Gene Is Associated With Triglyceride Levels In Subjects With Family History Of Hypertension From The SAPPHIRe And TWB Projects. Int J Med Sci. 2018;15(10):1035-1042.

     

     

  330. Cappel M, Mauger D, Thiboutot D. Correlation between serum levels of insulin-like growth factor 1, dehydroepiandrosterone sulfate, and dihydrotestosterone and acne lesion counts in adult women. ArchDermatol.2005;141(3):333-8.

     

     

  331. Sjögren K, Wallenius K, Liu JL, et al. Liver-derived IGF-I is of importance for normal carbohydrate and lipid metabolism. Diabetes. 2001;50(7):1539-45.

     

     

  332. Dichtel LE, Corey KE, Misdraji J, et al. The Association Between IGF-1 Levels and the Histologic Severity of Nonalcoholic Fatty Liver Disease. Clinical and Translational Gastroenterology. 2017;8(1):e217-. doi:10.1038/ctg.2016.72.

     

     

  333. Romero MJ, Lucas R, Dou H, et al. Role of growth hormone-releasing hormone in dyslipidemia associated with experimental type 1 diabetes. Proc Natl Acad Sci USA. 2016;113(7):1895-900.
Shopping Cart

Product Index :

Alcohol and Drug Withdrawal:

Epithalon

DSIP

Anti-Aging & Longevity:

5-amino-1mq

Glutathione

AICAR

Epithalon

MOTS-C

FOXO4-DRI (Proxofim)

Blood Sugar Control:

Semaglutide (Tablets)

Adipotide

AICAR

Tirzepatide

Semaglutide

Brain, CNS and Nerves:

Oxytocin Acetate

Semax

Selank

Focus and Energy:

5-amino-1mq

SS-31

GHK-CU

Gut and Digestion:

BPC-157 (Tablets)

BPC 5mg + TB 5mg

BPC-157

LL-37

Immune Regulation:

Thymosin Alpha-1

AICAR

Injury Healing and Recovery:

BPC-157 (Tablets)

BPC 5mg + TB 5mg

TB500 Thymosin B4 Acetate

BPC-157

Muscle and Strength:

Cabergoline/Dostinex

17a-Methyl-1-testosterone M1T

Hexarelin Acetate

IGF-DES

IGF-1LR3

GDF-8

Muscle Growth:

Test

Flibanserin

Finasteride

Cabergoline/Dostinex

17a-Methyl-1-testosterone M1T

Semaglutide (Tablets)

Pain and Inflammation:

BPC-157 (Tablets)

Thymalin

BPC 5mg + TB 5mg

AICAR

BPC-157

DSIP

Sexual Wellness:

Flibanserin

Triptorelin/Acetate/GnRH

Gonadorelin Acetate

PT-141

Follistatin

KissPeptin-10

Skin:

MT-2 (Melanotan 2 Acetate)

Sleep:

Melatonin

DSIP

MT-2 (Melanotan 2 Acetate)

Weight Management:

Cabergoline/Dostinex

Semaglutide (Tablets)

TB500 Tesofensine

5-amino-1mq

GLP-1

CJC-1295 Without DAC 5mg + Ipomorelin 5mg